CN101891802B - Polypeptide or derivative product for treating or preventing cancer and application thereof - Google Patents
Polypeptide or derivative product for treating or preventing cancer and application thereof Download PDFInfo
- Publication number
- CN101891802B CN101891802B CN2009101638521A CN200910163852A CN101891802B CN 101891802 B CN101891802 B CN 101891802B CN 2009101638521 A CN2009101638521 A CN 2009101638521A CN 200910163852 A CN200910163852 A CN 200910163852A CN 101891802 B CN101891802 B CN 101891802B
- Authority
- CN
- China
- Prior art keywords
- cancer
- peptide
- seq
- polypeptide
- platinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 199
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 68
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 67
- 201000011510 cancer Diseases 0.000 title claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 title abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 229940063179 platinol Drugs 0.000 claims description 89
- 238000011282 treatment Methods 0.000 claims description 21
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 201000000498 stomach carcinoma Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 101000756400 Human T-cell leukemia virus 2 Protein Rex Proteins 0.000 claims description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001221 pirarubicin Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 16
- 238000002512 chemotherapy Methods 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 99
- 210000004027 cell Anatomy 0.000 description 84
- 230000002401 inhibitory effect Effects 0.000 description 37
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 32
- 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 32
- 239000011347 resin Substances 0.000 description 30
- 229920005989 resin Polymers 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000000452 restraining effect Effects 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000006101 laboratory sample Substances 0.000 description 9
- 150000003053 piperidines Chemical class 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000000890 drug combination Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 231100000636 lethal dose Toxicity 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010336 energy treatment Methods 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- -1 tetramethyl-urea hexafluorophosphate Chemical compound 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- DYDKXJWQCIVTMR-WDSKDSINSA-N Asp-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O DYDKXJWQCIVTMR-WDSKDSINSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WSDOHRLQDGAOGU-BQBZGAKWSA-N His-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 WSDOHRLQDGAOGU-BQBZGAKWSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a polypeptide or a derivative product for treating or preventing cancer and the application thereof, which belong to the field of biological medicaments. An amino acid sequence of the polypeptide of the invention is expressed by SEQ ID NO.1 or SEQ ID NO.2. The invention also discloses a product obtained by conjugating or mixing the polypeptide and a preparation promoting the accumulation of the polypeptide in cells. The polypeptide of the invention can be independently used for treating and preventing the cancer; when jointly applied with chemotherapy medicaments, the polypeptide can obviously improve the capacity of selectively killing cancer cells of the chemotherapy medicaments and obviously reduce the onset dosage of the chemotherapy medicaments; and the polypeptide of the invention has low toxic action on normal cells, so that the toxicity and side effects of the chemotherapy medicaments are effectively reduced. The polypeptide of the invention can be prepared by using a chemical synthesis method and has the advantages of high purity, small molecular weight, strong specificity, no immunogenicity, safety and reliability.
Description
Technical field
The present invention relates to polypeptide and uses thereof, relate in particular to and to treat or the polypeptide of preventing cancer, the invention still further relates to the product that has treatment or preventing cancer effect by this peptide institute deutero-, the invention belongs to biomedicine field.
Background technology
The sickness rate of China's malignant tumour is obvious ascendant trend in recent years, and tumour has become serious threat and one of principal disease of human security and health.The statistical information of ministry of Health of China shows: about about 2,200,000 people of the annual newborn tumour patient sum of China, wherein, the newborn patient of malignant tumour about 1,210,000 is arranged every year at present, account for 55% of the annual newborn tumour patient sum of China; Simultaneously, the whole nation has the existing patient of the tumour about 3,100,000 approximately, and wherein, the existing patient of malignant tumour is about about 1,820,000, accounts for the existing tumour patient sum 58% of China.At present, chemotherapy is still one of main means of oncotherapy, can predict, and along with the growth of tumor incidence, will further increase the demand of antitumor drug.
Platinol is the metal complex of at first finding the sixties in last century, has anti-tumor activity, and clinical confirmation Platinol in 1971 has the intensive inhibitory or killing effect to some tumour of human body.The antitumor spectra of Platinol is wider, be a line medicine (the external medicine of Li Yixin (translating) " choice drug of the cancer chemotherapeutic "-biochemical medicine preparation of synthetic drug fascicle for the treatment of mammary cancer, ovarian cancer, carcinoma of testis at present, 89-101,19,1998), and normal and other chemotherapeutic such as Etoposide, bleomycin, Zorubicin and 5 FU 5 fluorouracil share the cancer for the treatment of head, neck and cancer of the stomach etc.The main drawback of Platinol cancer therapy drug has: (1) toxic side effects is serious: comprise renal toxicity, gastrointestinal toxicity, ototoxicity and neurotoxicity; (2) lower to some oncocyte activity: as mammary cancer, colorectal carcinoma etc.; (3) easily produce resistance; (4) water-soluble little, be difficult for metabolism in vivo; (5) must drug administration by injection (surplus nation is good etc., " platinum-containing anticancer drug progress " University Of Hainan journal natural science edition, 72-80,23,2005).Therefore, improve the drug effect of antineoplastic chemotherapy medicine and to reduce medicine be the medical educational circles continuous goal in research of effort always to normal histiocytic toxicity.
From publication number is to recognize RasGAP the CN 1816564A Chinese patent application in (open August 9 2006 date)
317-326Toplink is strengthened the ability that Platinol kills and wounds cancer cells, RasGAP
317-326The chemotherapeutics that peptide must and can kill and wound cancer cells share the competence exertion effect, and the sensitization of this peptide is limited; And it does not have restraining effect to cancer cells when the concentration of Platinol is 0 μ M.
Summary of the invention
Purpose of the present invention overcomes the deficiencies in the prior art, the polypeptide and the derived product thereof of a kind of energy treatment or preventing cancer are provided, described polypeptide or its derived product can not only be used for the treatment of separately or preventing cancer, and when itself and gene toxin coupling significantly the enhancing gene toxin optionally kill and wound the ability of cancer cells.
The inventor finds that through after the deep research a kind of polypeptide with the listed feature in the following technical proposals can achieve the above object.
The polypeptide of a kind of energy treatment or preventing cancer, its aminoacid sequence is shown in the SEQ ID NO.1.
The polypeptide of a kind of energy treatment or preventing cancer, its aminoacid sequence is shown in the SEQ ID NO.2.
The nucleotide sequence of a kind of separation and purifying, the polypeptide of its aminoacid sequence shown in SEQ ID NO.1 or the SEQ ID NO.2 of encoding.
A kind of expression vector, the encoding amino acid sequence that comprises at least one copy are the nucleotide sequence of polypeptide shown in SEQ ID NO.1 or the SEQ ID NO.2.
A kind of protokaryon or eukaryotic host cell, this host cell contains above-mentioned expression vector.
The present invention also further provide with SEQ ID NO.1 or the described polypeptide of SEQ ID NO.2 with can increase its preparation that in cell, accumulates and put together or mix the resulting product in back mutually.
The preparation that above-mentioned and described peptide is puted together is the carrier that can assist described peptide permeates cell membranes.SEQ IDNO.1 or the described peptide of SEQ ID NO.2 and the carrier that can assist the peptide permeates cell membranes, as the HIV48-57 peptide, FHV-is outer by the 35-49 peptide, HTLV-II Rex 4-16 peptide or BMV gag7-25 peptide are puted together, the compound of puting together the back generation can effectively pass through cytolemma, work in the cancer cells part, therefore have the stronger effect of killing and wounding cancer cells.
Can also be nano material, liposome or oiliness compound with the preparation of SEQ ID NO.1 or the described conjugation of polypeptides of SEQ ID NO.2.
SEQ ID NO.1 or the described polypeptide of SEQ ID NO.2 and macromolecular materials such as nano material, liposome are puted together, and the compound of puting together the back generation can make the polypeptide that the present invention relates to more stably be transported to target cell in body.The polypeptide that the present invention relates to also can mix mutually with the mixture of oiliness compound or multiple oiliness compound, and resulting mixture also can make polypeptide of the present invention more stably be transported to target cell in body.
The medicinal compositions of a kind of treatment or preventing cancer comprises: as SEQ ID NO.1 or the SEQ ID NO.2 peptide and pharmaceutical carrier, thinner and/or adjuvant composition of the medicinal significant quantity of active substance.
The present invention also provides SEQ ID NO.1 or the described polypeptide of SEQ ID NO.2 to be used for preparing the purposes of the medicine of treatment or preventing cancer.
Described cancer includes but not limited to: lung cancer, liver cancer, cancer of the stomach, colorectal carcinoma, the rectum cancer, the esophageal carcinoma, mammary cancer, leukemia, bladder cancer, cervical cancer or nasopharyngeal carcinoma etc.
The present invention also provides SEQ ID NO.1 or the described polypeptide of SEQ ID NO.2 has been used for preparing the purposes that the enhancing gene toxin optionally kills and wounds the medicine of cancer cells.
Described cancer cells includes but not limited to: cancer cells such as lung cancer, liver cancer, cancer of the stomach, colorectal carcinoma, the rectum cancer, the esophageal carcinoma, mammary cancer, leukemia, bladder cancer, cervical cancer or nasopharyngeal carcinoma.
Described gene toxin includes but not limited to: Platinol, oxaliplatin, taxol, epirubicin, Dx, pirarubicin, daunorubicin, mitomycin, Dacarbazine, endoxan, gemcitabine or capecitabine etc.
Polypeptide of the present invention can add acceptable accessories again with the gene toxin mixing or carrier obtains more effective cancer therapy drug.
Polypeptide of the present invention normally uses with the consumption that can realize intended purposes.When being used for prevention and treatment cancer, polypeptide of the present invention or its medicinal compositions are taken with the treatment significant quantity or are used.For systemic medication, can be according to experiment in vitro estimation treatment significant quantity or consumption, the common method that can also use this area estimates the intravital initial dose of polypeptide of the present invention by animal model.Certainly, the concrete significant quantity of polypeptide of the present invention will depend on severity, application method and doctor in charge's the clinical judgment of body weight, the disease of concrete treatment target, treatment target.
The inventor finds later on above-mentionedly to can be used for treating or the polypeptide of preventing cancer through deep research.This polypeptide not only has tangible lethality to cancer cells when using separately, and can share with chemotherapeutics (as Platinol) commonly used clinically, increase the susceptibility of chemotherapeutics significantly, strengthen its lethality, reduce its using dosage cancer cells to cancer cells.Polypeptide of the present invention can be to lung cancer, liver cancer, and cancer of the stomach, colorectal carcinoma, the rectum cancer, the esophageal carcinoma, mammary cancer, multiple cancer cells such as leukemia plays lethal effect.Polypeptide of the present invention has antitumor action; The effect that polypeptide of the present invention and Platinol share cancer cells significantly is better than RasGAP
317-326Peptide (RasGAP
317-326The amino acid residue sequence of peptide is: the WMWVTNLRTD) effect of share with Platinol.The polypeptide that the present invention relates to does not have tangible toxicity enhancement to normal cell, and the polypeptide that the present invention relates to can adopt the method for chemosynthesis to prepare, the purity height, and molecular weight is little, high specificity, non-immunogenicity, safe and reliable.
Polypeptide of the present invention can be used for treatment for cancer and prevention separately and good effect is arranged, polypeptide of the present invention can also and chemotherapeutics (as Platinol, taxol etc.) share, can selectivity strengthen the susceptibility of chemotherapeutics to tumour cell, obviously reduced the onset dosage of chemotherapeutics, because little, thereby the toxicity and the side effect of chemotherapeutics have been reduced to Normocellular toxic action.
Description of drawings
Fig. 1 represents that HPLC detects purifying RasGAP later on
317-326The characteristic peak figure of peptide wash-out on analytical column.
Fig. 2 represents that HPLC detects the purifying characteristic peak figure of the described polypeptide of SEQ ID NO.1 wash-out on analytical column later on.
Fig. 3 represents that HPLC detects the purifying characteristic peak figure of the described polypeptide of SEQ ID NO.2 wash-out on analytical column later on.
Fig. 4 SEQ ID NO.1, SEQ ID NO.2, RasGAP
317-326Peptide and Platinol are respectively to the restraining effect result of tumour cell.
Fig. 5 SEQ ID NO.1, SEQ ID NO.2, RasGAP
317-326Peptide and Platinol share the restraining effect result of back to tumour cell respectively.
Fig. 6 SEQ ID NO.1, SEQ ID NO.2, RasGAP
317-326Peptide and Platinol share the back respectively to normal cell inhibiting exercising result.
Fig. 7 SEQ ID NO.1, SEQ ID NO.2, RasGAP
317-326Peptide and Platinol are respectively to normal cell inhibiting exercising result.
Fig. 8 SEQ ID NO.1 peptide and Platinol share the restraining effect result to stomach cancer cell.
Fig. 9 SEQ ID NO.1 peptide and Platinol share the restraining effect result to lung carcinoma cell.
Figure 10 SEQ ID NO.1 peptide and Platinol share the restraining effect result to colon cancer cell.
Figure 11 SEQ ID NO.2 peptide and Platinol share the restraining effect result to colon cancer cell.
SEQ?ID?NO.1：FLKGDMFIVHNELEDG
SEQ?ID?NO.2：FLKGDMFIVHNELEDGWMWVT
Embodiment
Further describe the present invention below in conjunction with specific embodiment, advantage of the present invention and characteristics will be more clear along with description.But these embodiment only are exemplary, scope of the present invention are not constituted any restriction.It will be understood by those skilled in the art that and down can make amendment or replace without departing from the spirit and scope of the present invention, but these modifications and replacing all fall within the scope of protection of the present invention the details of technical solution of the present invention and form.
1) laboratory apparatus and material:
Dimethyl formamide (DMF), piperidines, resin, methylene dichloride (DCM), Kaiser test kit, I-hydroxybenzotriazole (HOBt), tetramethyl-urea hexafluorophosphate (HBTU), diisopropylethylamine (DIEA), methyl alcohol, each seed amino acid, polypeptide solid phase synthesis pipe.
2) experimental procedure:
The weighing resin is also put in the polypeptide solid phase synthesis pipe (hereinafter to be referred as reactor), adds an amount of DMF swelling 10 minutes.Take out DMF and carry out the Fmoc protective reaction, promptly add the DMF solution that contains 20% piperidines in right amount, fully stir, take out solution after 5 minutes, the DMF solution that adds 20% piperidines again goes to protect 7 minutes.Take out and protect liquid, use DMF washing resin 4-5 time, take out DMF; with DCM washing 1-2 time, (about 5～10mg) in test tube, uses washing with alcohol 2 times for the resin that takes a morsel from reactor; the Kaiser method detects and the record color, prepares to feed intake, and enters the amino acid condensation reaction.According to RasGAP
317-326The aminoacid sequence of peptide is got corresponding amino acid, HOBt in proper order in proper container, with the DMF dissolving, adds DIEA activation 5 minutes after the dissolving fully, adds load weighted HBTU, and ice-water bath dissolving down activates 5 minutes, puts in the reactor stirring reaction.After 90 minutes, take a morsel resin from reactor in test tube, use washing with alcohol 2 times, the Kaiser method detects.Take out the liquid in the reactor,, take out DMF, obtain the peptide resin behind first amino acid condensation with DMF washing 2 times.The gained peptide resin is repeated above " Fmoc go protection---amino acid condensation " reactions steps, finish to last amino acid reaction, obtain RasGAP
317-326Peptide.Adopt aforesaid method, according to HIV
48-57The sequence of peptide is at RasGAP
317-326Continue chemosynthesis on the peptide and connect corresponding amino acid, obtain having puted together HIV
48-57RasGAP
317-326Peptide.After reaction finished, DCM washing resin 2-3 time was taken out solvent, added methyl alcohol and stirred contraction (5min+5min), took out methyl alcohol, continued to drain 15-20min.Take out the peptide resin that has synthesized in the reactor, transfer to round-bottomed flask, in moisture eliminator, drain cracking at room temperature two hours.Solution behind the resin filter is concentrated freeze-dried under vacuum.Thick peptide uses Tianjin, island LC-6AD to prepare type reversed-phase HPLC purifying, uses HPLC to detect purity＞90%.Resulting pure peptide uses mass spectrum, and (MS identifies that electrospray) its molecular weight is 2813.29, and is consistent with calculated value 2813.29.
Synthesizing of the described peptide of embodiment 2 SEQ ID NO.1
1) laboratory apparatus and material:
Dimethyl formamide (DMF), piperidines, resin, methylene dichloride (DCM), Kaiser test kit, I-hydroxybenzotriazole (HOBt), tetramethyl-urea hexafluorophosphate (HBTU), diisopropylethylamine (DIEA), methyl alcohol, each seed amino acid, polypeptide solid phase synthesis pipe.
2) experimental procedure:
The weighing resin is also put in the polypeptide solid phase synthesis pipe (hereinafter to be referred as reactor), adds an amount of DMF swelling 10 minutes.Take out DMF and carry out the Fmoc protective reaction, promptly add the DMF solution that contains 20% piperidines in right amount, fully stir, take out solution after 5 minutes, the DMF solution that adds 20% piperidines again goes to protect 7 minutes.Take out and protect liquid, use DMF washing resin 4-5 time, take out DMF; with DCM washing 1-2 time, (about 5～10mg) in test tube, uses washing with alcohol 2 times for the resin that takes a morsel from reactor; the Kaiser method detects and the record color, prepares to feed intake, and enters the amino acid condensation reaction.Order according to the aminoacid sequence of the described peptide of SEQ ID NO.1 takes by weighing corresponding amino acid, HOBt in proper container, and with the DMF dissolving, dissolving back fully adds DIEA activation 5 minutes, add load weighted HBTU, ice-water bath dissolving down activates 5 minutes, puts in the reactor stirring reaction.After 90 minutes, take a morsel resin from reactor in test tube, use washing with alcohol 2 times, the Kaiser method detects.Take out the liquid in the reactor,, take out DMF, obtain the peptide resin behind first amino acid condensation with DMF washing 2 times.The gained peptide resin is repeated above " Fmoc go protection---amino acid condensation " reactions steps, finish to last amino acid reaction of SEQ ID NO.1 sequence, obtain SEQ ID NO.1 peptide.Adopt aforesaid method, according to HIV
48-57The sequence of peptide continues chemosynthesis and connects corresponding amino acid on SEQ ID NO.1 peptide, obtain having puted together HIV
48-57SEQ ID NO.1 peptide.After reaction finished, DCM washing resin 2-3 time was taken out solvent, added methyl alcohol and stirred contraction (5min+5min), took out methyl alcohol, continued to drain 15-20min.Take out the peptide resin that has synthesized in the reactor, transfer to round-bottomed flask, in moisture eliminator, drain cracking at room temperature two hours.Solution behind the resin filter is concentrated freeze-dried under vacuum.Thick peptide uses Tianjin, island LC-6AD to prepare type reversed-phase HPLC purifying, uses HPLC to detect purity＞90%.Resulting pure peptide uses mass spectrum, and (MS identifies that electrospray) its molecular weight is 3411.01, and is consistent with calculated value 3412.96.
According to the method described above can be the outer quilt of FHV-
35-49Peptide, HTLV-II Rex
4-16Peptide or BMV gag
7-25Peptide and SEQ ID NO.1 peptide of the present invention are conjugated in together.
Synthesizing of the described peptide of embodiment 3 SEQ ID NO.2
1) instrument and material:
Dimethyl formamide (DMF), piperidines, resin, methylene dichloride (DCM), Kaiser test kit, I-hydroxybenzotriazole (HOBt), tetramethyl-urea hexafluorophosphate (HBTU), diisopropylethylamine (DIEA), methyl alcohol, each seed amino acid, polypeptide solid phase synthesis pipe.
2) experimental procedure:
The weighing resin is also put in the polypeptide solid phase synthesis pipe (hereinafter to be referred as reactor), adds an amount of DMF swelling 10 minutes.Take out DMF and carry out the Fmoc protective reaction, promptly add the DMF solution that contains 20% piperidines in right amount, fully stir, take out solution after 5 minutes, the DMF solution that adds 20% piperidines again goes to protect 7 minutes.Take out and protect liquid, use DMF washing resin 4-5 time, take out DMF; with DCM washing 1-2 time, (about 5～10mg) in test tube, uses washing with alcohol 2 times for the resin that takes a morsel from reactor; the Kaiser method detects and the record color, prepares to feed intake, and enters the amino acid condensation reaction.Aminoacid sequence according to the described peptide of SEQ ID NO.2 takes by weighing corresponding amino acid, HOBt in proper container, and with the DMF dissolving, dissolving back fully adds DIEA activation 5 minutes, add load weighted HBTU, ice-water bath dissolving down activates 5 minutes, puts in the reactor stirring reaction.After 90 minutes, take a morsel resin from reactor in test tube, use washing with alcohol 2 times, the Kaiser method detects.Take out the liquid in the reactor,, take out DMF, obtain the peptide resin behind first amino acid condensation with DMF washing 2 times.The gained peptide resin is repeated above " Fmoc go protection---amino acid condensation " reactions steps, finish to last amino acid reaction of SEQ ID NO.2 sequence, obtain SEQ ID NO.2 peptide.Adopt aforesaid method, according to HIV
48-57The sequence of peptide continues chemosynthesis and connects corresponding amino acid on SEQ IDNO.2 peptide, obtain having puted together HIV
48-57SEQ ID NO.2 peptide.After reaction finished, DCM washing resin 2-3 time was taken out solvent, added methyl alcohol and stirred contraction (5min+5min), took out methyl alcohol, continued to drain 15-20min.Take out the peptide resin that has synthesized in the reactor, transfer to round-bottomed flask, in moisture eliminator, drain cracking at room temperature two hours.Solution behind the resin filter is concentrated freeze-dried under vacuum.Thick peptide uses Tianjin, island LC-6AD to prepare type reversed-phase HPLC purifying, uses HPLC to detect purity＞90%.Resulting pure peptide uses mass spectrum, and (MS identifies that electrospray) its molecular weight is 4660.41, meets calculated value.
According to the method described above can be the outer quilt of FHV-
35-49Peptide, HTLV-II Rex
4-16Peptide or BMV gag
7-25Peptide and SEQ ID NO.2 peptide of the present invention are conjugated in together.
Experimental example 1 mtt assay detects SEQ ID NO.1, SEQ ID NO.2 and RasGAP
317-326Peptide is tested the restraining effect of tumour cell respectively
One, laboratory sample: embodiment 1-3 institute synthetic polypeptide: RasGAP
317-326Peptide, SEQ ID NO.1 peptide, SEQ ID NO.2 peptide;
Two, experimental technique
Human cervical carcinoma cell strain Hela (purchasing in China typical culture collection center Wuhan University center) is suspended in the RPMI1640 nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cell is at 37 ℃, 5%CO
2Cultivate.When cell density reaches 70%-80%, add Platinol, RasGAP
317-326Peptide, the described peptide of SEQ ID NO.1 or the described peptide of SEQ ID NO.2, wherein every kind of drug concentrations gradient is 40 μ mol/L, 30 μ mol/L, 20 μ mol/L, 10 μ mol/L, 0 μ mol/L, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds dimethyl sulfoxide (DMSO) (DMSO) 150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Data statistics is represented with mean ± standard deviation, adopts the t check.
Three, experimental result:
As seen from Figure 4, generally SEQ ID NO.1, the described polypeptide of SEQ ID NO.2 to the Hela cell inhibiting effect compare RasGAP
317-326Peptide is remarkable.When medicine at lower concentration, that is: when concentration was less than 10 μ mol/L, SEQ ID NO.1, the described peptide of SEQ ID NO.2 just had restraining effect to the Hela cell and than the Platinol or the RasGAP of same concentrations
317-326The effect of peptide is more obvious, and significant difference has statistical significance between the two.SEQ ID NO.1, the described peptide of SEQ ID NO.2 have significant inhibitory effect to the Hela cell, and the RasGAP of same concentrations
317-326Peptide does not almost have restraining effect to the Hela cell.Illustrate that polypeptide of the present invention can be used as the medicine of treatment and preventing cancer.
Experimental example 2 mtt assay detect different peptides and Platinol and share effect experiment to tumour cell
One, laboratory sample: embodiment 1-3 institute synthetic polypeptide: RasGAP
317-326Peptide, SEQ ID NO.1 peptide, SEQ ID NO.2 peptide;
Two, experimental technique
Human cervical carcinoma cell strain Hela is suspended in the RPMI1640 nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cultivate after 24 hours, add Platinol and RasGAP respectively
317-326The peptide mixed solution, described peptide mixed solution of Platinol and SEQ ID NO.1 or Platinol and the described peptide mixed solution of SEQ ID NO.2.Wherein the Platinol concentration gradient is 1.1 μ mol/L, 0.37 μ mol/L, 0.12 μ mol/L, 0 μ mol/L in every kind of mixed solution, and each peptide final concentration is 20 μ mol/L, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds DMSO 150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Data statistics is represented with mean ± standard deviation, adopts the t check.
Three, experimental result:
As seen from Figure 5, when Platinol and SEQ ID NO.1 share or share with SEQ ID NO.2 peptide, perhaps with RasGAP
317-326When peptide share, they all obviously were better than independent use Platinol to the effect of Hela cell inhibiting, illustrated that polypeptide of the present invention can increase the susceptibility of Platinol to the Hela cell, strengthened it to the effect of Hela cell inhibiting.Three peptide species are different to increasing Platinol to the ability of Hela cellular sensitivity in this experiment, and wherein the described peptide of SEQ ID NO.2 is the most obvious to the sensitization of Platinol, secondly is the described peptide of SEQ ID NO.1; When the concentration of Platinol was 0 μ mol/L, the described peptide of SEQ IDNO.1, the described peptide of SEQ ID NO.2 were respectively 17.6% and 17.7% to Hela cell inhibiting rate, and RasGAP
317-326The inhibiting rate of peptide only is 2.5%, and described peptide of SEQ ID NO.1 and the described peptide of SEQ ID NO.2 are better than RasGAP to the sensitization of Platinol
317-326Peptide is to the sensitization of Platinol, and has statistical significance.
Experimental example 3 mtt assay detect different peptides and Platinol share normal cell inhibiting effect experiment
One, laboratory sample: embodiment 1-3 institute synthetic polypeptide: RasGAP
317-326Peptide, SEQ ID NO.1 peptide, SEQ ID NO.2 peptide;
Two, experimental technique
People sarcoplast (purchasing the Shanghai cell bank in the Chinese Academy of Sciences) is suspended in the RPMI1640 nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cultivate after 24 hours, when cell density reaches 70%-80%, add Platinol and RasGAP respectively
317-326The mixed solution of the mixed solution of the mixed solution of peptide, Platinol and the described peptide of SEQ ID NO.1, Platinol and the described peptide of SEQ ID NO.2.Wherein the concentration gradient of Platinol is 250 μ mol/L, 200 μ mol/L, 150 μ mol/L, 100 μ mol/L, 50 μ mol/L, 0 μ mol/L, and the final concentration of polypeptide is 20 μ mol/L, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds DMSO 150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Three, experimental result:
As seen from Figure 6, when Platinol and the SEQ ID NO.1 of 50 μ mol/L share, when perhaps share, the myoblastic inhibiting rate of people is respectively 17% and 9.6%, uses same concentrations Platinol or same concentrations Platinol and RasGAP separately with the described peptide of SEQ ID NO.2
317-326Peptide share, and its inhibiting rate is respectively 25.3% and 29.1%.Progressively increase along with Platinol concentration, Platinol and SEQ IDNO.1 share or share with the described peptide of SEQ ID NO.2 the myoblastic restraining effect of people is also progressively strengthened, but compare with independent use same concentrations Platinol or with same concentrations Platinol and RasGAP
317-326Peptide share compares not notable difference.Experimental result shows when polypeptide of the present invention and Platinol share that to normal cell nontoxicity enhancement, polypeptide promptly of the present invention is little to normal cell nontoxicity or toxicity.
Experimental example 4 mtt assay detect SEQ ID NO.1, SEQ ID NO.2 and RasGAP
317-326Peptide is respectively to normal cell inhibiting effect experiment
One, laboratory sample: embodiment 1-3 institute synthetic polypeptide: RasGAP
317-326Peptide, SEQ ID NO.1 peptide, SEQ ID NO.2 peptide;
Two, experimental technique
People sarcoplast (purchasing the Shanghai cell bank in the Chinese Academy of Sciences) is suspended in the RPMI1640 nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cultivate after 24 hours, when cell density reaches 70%-80%, add Platinol, RasGAP respectively
317-326Peptide, the described peptide of SEQID NO.1, the described peptide of SEQ ID NO.2, wherein every kind of drug concentrations gradient is 80 μ mol/L, 40 μ mol/L, 20 μ mol/L, 10 μ mol/L, 0 μ mol/L, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds DMSO150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Three, experimental result
Platinol has tangible lethal effect to the people sarcoplast as seen from Figure 7, and the described peptide of SEQ ID NO.1 of same concentrations, the described peptide of SEQ ID NO.2, RasGAP
317-326Peptide is less to the myoblastic lethal effect of people, and the described peptide of SEQ ID NO.1 promptly of the present invention, the described peptide of SEQ ID NO.2 do not have obvious lethal effect to normal cell.
Experimental example 5 mtt assay detection SEQ ID NO.1 peptide and Platinol share the effect to people's cancer of the stomach SGC-7901 cell
One, 2 synthetic SEQ of laboratory sample: embodiment ID NO.1 peptide;
Two, experimental technique
Human stomach cancer cell line SGC-7901 (purchasing in China typical culture collection center Wuhan University center) is suspended in the RPMI1640 nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cultivate after 24 hours, control group adds Platinol, and experimental group adds Platinol and the described peptide mixed solution of SEQ ID NO.1.Wherein the Platinol concentration gradient is 90 μ mol/L, 30 μ mol/L, 10 μ mol/L, 3.3 μ mol/L, 1.1 μ mol/L, 0.37 μ mol/L in control group and the experimental group, the described peptide final concentration of SEQ ID NO.1 is 20 μ mol/L in the experimental group mixed solution, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds DMSO 150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Three, experimental result:
As seen from Figure 8, when Platinol and SEQ ID NO.1 share, effect obviously is better than independent use Platinol to the SGC-7901 cell inhibiting for they, illustrate that SEQ ID NO.1 can increase the susceptibility of Platinol to the SGC-7901 cell, strengthen it the effect of SGC-7901 cell inhibiting.
Experimental example 6 mtt assay detection SEQ ID NO.1 peptide and Platinol share the effect experiment to people's lung cancer A549 cell
One, 2 synthetic SEQ of laboratory sample: embodiment ID NO.1 peptide;
Two, experimental technique
Human lung carcinoma cell line A549 (purchasing in China typical culture collection center Wuhan University center) is suspended in the F-12K nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cultivate after 24 hours, control group adds Platinol, and experimental group adds Platinol and the described peptide mixed solution of SEQ IDNO.1.Wherein the Platinol concentration gradient is 90 μ mol/L, 30 μ mol/L, 10 μ mol/L, 3.3 μ mol/L, 1.1 μ mol/L, 0.37 μ mol/L in control group and the experimental group, the described peptide final concentration of SEQ ID NO.1 is 20 μ mol/L in the experimental group mixed solution, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds DMSO150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Three, experimental result:
As seen from Figure 9, when Platinol and the described peptide of SEQ ID NO.1 share, effect obviously is better than independent use Platinol to the A549 cell inhibiting for they, illustrate that the described peptide of SEQ ID NO.1 can increase the susceptibility of Platinol to the A549 cell, strengthens it to the effect of A549 cell inhibiting.
Experimental example 7 mtt assay detection SEQ ID NO.1 peptide, SEQ ID NO.2 peptide share with Platinol respectively the effect of human colon carcinoma HCT-116 cell are tested
One, 2 synthetic SEQ of laboratory sample: embodiment ID NO.1 peptide, 3 synthetic SEQ of embodiment IDNO.2 peptide;
Two, experimental technique
Human colon cancer cell strain HCT-116 (purchasing the Shanghai cell bank in the Chinese Academy of Sciences) is suspended in the RPMI1640 nutrient solution that contains 10% heat-inactivated fetal bovine serum, is inoculated in 96 orifice plates with the density in 5000-10000/hole.Cultivate after 24 hours, control group adds Platinol, and experimental group adds Platinol and the mixed solution of the described peptide of SEQ ID NO.1 or the mixed solution of Platinol and the described peptide of SEQ ID NO.2.Wherein the Platinol concentration gradient is 90 μ mol/L, 30 μ mol/L, 10 μ mol/L, 3.3 μ mol/L, 1.1 μ mol/L, 0.37 μ mol/L in control group and the experimental group, the described peptide final concentration of described peptide of SEQ ID NO.1 or SEQ ID NO.1 is 20 μ mol/L in the experimental group mixed solution, and each concentration is established 3 multiple holes.Continue to cultivate every hole adding MTT (5mg/ml) 20 μ l after 20 hours, inhale after 4 hours and remove nutrient solution, every hole adds DMSO 150 μ l, shakes purple crystal fully to be dissolved in 10 minutes.Microplate reader 570nm measures absorbancy.
Cell inhibitory rate is calculated as follows:
Cell inhibitory rate=(blank group OD value-experimental group OD value)/blank group OD value * 100%
Three, experimental result:
As seen from Figure 10, when Platinol and SEQ ID NO.1 share, effect obviously is better than independent use Platinol to the HCT-116 cell inhibiting for they, illustrate that SEQ ID NO.1 can increase the susceptibility of Platinol to the HCT-116 cell, strengthens its restraining effect to the HCT-116 cell.
As seen from Figure 11, when Platinol and SEQ ID NO.2 share, effect obviously is better than independent use Platinol to the HCT-116 cell inhibiting for they, illustrate that SEQ ID NO.2 can increase the susceptibility of Platinol to the HCT-116 cell, strengthens its restraining effect to the HCT-116 cell.
IC
50Aspect apoptosis, can be understood as certain density certain drug-induced apoptosis of tumor cells 50%, this concentration is called 50% inhibition concentration, be apoptotic cell and the ratio of whole cell count equals 50% o'clock pairing concentration, the IC50 value can be used for weighing the ability of drug-induced apoptosis, be that inducibility is strong more, this numerical value is low more, can certainly certain cell of reverse instruction to the tolerance degree of medicine.SEQ ID NO.1 and Platinol share the result of human tumor cells effect as shown in table 1, restraining effect to tumour cell when SEQ ID NO.1 and Platinol share is obvious, and SEQ ID NO.1 peptide uses separately or and Platinol share Normocellular effect all smallerly, illustrate that peptide of the present invention can be used as the medicine of treatment and preventing cancer.
Table 1 SEQ ID NO.1 half-inhibition concentration (IC
50) observe
Medium lethal dose (LD50) experiment in the described peptide body of experimental example 8 SEQ ID NO.1
One, 2 synthetic SEQ of laboratory sample: embodiment ID NO.1 peptide;
Two, experimental technique: BALB/c kind mouse, male (the purchasing in Beijing Vital River Experimental Animals Technology Co., Ltd.) of 18-22 gram body weight used in experiment.The described peptide of SEQ ID NO.1 is established 125mg/kg, 250mg/kg, four dosage groups of 500mg/kg, 1000mg/kg, and through intraperitoneal administration once, 30 days finish experiment after the administration, weighs statistics animals survived number of elements.
Three, experimental result: the described peptide 125mg/kg of SEQ ID NO.1,250mg/kg, 500mg/kg, four dosage groups of 1000mg/kg, every group of 5 animals, through intraperitoneal administration once, when 30 days finished experiment after the administration, animal all survived.Experimental result sees Table 2, the LD50＞1000mg/kg of the described peptide of experimental result proof SEQ ID NO.1.
Table 2.SEQ ID NO.1 peptide medium lethal dose (LD50) is observed
The described peptide anti-tumor in vivo of experimental example 9 SEQ ID NO.1 effect experiment
One, 2 synthetic SEQ of laboratory sample: embodiment ID NO.1 peptide;
Two, experimental technique: test BALB/c kind male mice (purchasing) in Beijing Vital River Experimental Animals Technology Co., Ltd. with the 18-22 grammes per square metre.The tumor tissues and 0.85% physiological saline of colorectal carcinoma 26 cell mice with tumor (purchasing the biotechnology research institute in the Chinese Academy of Medical Sciences) ground to form cell suspension by 1: 10, and aseptic technique is at animal right side armpit subcutaneous vaccination tumour, every animal inoculation pvaccination 0.2ml.24 hours SEQ ID of inoculated tumour NO.1 peptide is through intraperitoneal administration, every day 1 time, totally 10 times.Platinol is through intraperitoneal administration, and 1 time every other day, totally 5 times; SEQ ID NO.1 peptide and Platinol 0.85% physiological saline solution, the intraperitoneal administration amount is the 0.2ml/20g body weight.Control group (0.85% physiological saline), SEQ ID NO.1 peptide various dose group, Platinol group and SEQ ID NO.1 peptide various dose and Platinol drug combination group are established in experiment.11 days finish experiment behind the inoculated tumour, weigh, and put to death animal, strip tumour, weigh.Be calculated as follows tumor control rate, and learn by statistics and handle, judging has there was no significant difference.
Tumor control rate=heavy * 100% medication combined evaluation of effect of the average knurl of (it is heavy that average knurl is organized in the average knurl weight-treatment of control group)/control group
Two medicine association indexs (combine index, CI) CI=AB/ (A * B).AB is the T/C ratio of two medicine combined action groups, and A and B are the separately T/C ratio of effect (two medicines have synergy when CI＜1 in theory) of medicine.
Three, experimental result:
SEQ ID NO.1 peptide and Platinol drug combination are to colorectal carcinoma 26 tumor tissues show dose dependent tumors restraining effect.SEQ ID NO.1 peptide dosage is respectively 25mg/kg, 50mg/kg, during 100mg/kg and Platinol dosage 1mg/kg drug combination in various degree tumor-inhibiting action is all arranged.The dosage 25mg/kg of SEQ ID NO.1 peptide, 50mg/kg, the tumour inhibiting rate of 100mg/kg is respectively 0%, 0% and 4%; The tumour inhibiting rate of the dosage 1mg/kg of Platinol is 22%.The dosage of SEQ ID NO.1 peptide is respectively 25mg/kg, 50mg/kg, and the tumour inhibiting rate of 100mg/kg and Platinol 1mg/kg drug combination is respectively 23% (P＜0.05), 30% and 34% (P＜0.01); Two medicine association indexs (CI) are respectively 0.99,0.90 and 0.88, show synergy.
In vivo test is the result show, SEQ ID NO.1 peptide and Platinol drug combination have the dose-dependent inhibition effect to mice transplanted tumor colorectal carcinoma 26 tumor growths, and SEQ ID NO.1 peptide and Platinol drug combination show collaborative the work
Table 3.SEQ ID NO.1 peptide and Platinol drug combination are to the effect of mouse junction cancer 26
Sequence table
＜110〉the triumphant safe true tumor technology in Wuhan company limited
＜120〉polypeptide or the derived product and the application thereof of treatment or preventing cancer
<160>2
<170>patentin?3.3
<210>1
<211>16
<212>PRT
<213>homo?sapiens
<400>1
Phe?Leu?Lys?Gly?Asp Met?Phe?Ile?Val?His Asn?Glu?Leu?Glu?Asp
1 5 10 15
Gly
<210>2
<211>21
<212>PRT
<213>homo?sapiens
<400>2
Phe?Leu?Lys?Gly?Asp Met?Phe?Ile?Val?His Asn?Glu?Leu?Glu?Asp
1 5 10 15
Gly?Trp?Met?Trp?Val Thr
20
Claims (13)
1. one kind has the peptide that kills and wounds the cancer cell effect, it is characterized in that, the aminoacid sequence of described peptide is shown in the SEQ ID NO.1.
2. one kind has the peptide that kills and wounds the cancer cell effect, it is characterized in that, the aminoacid sequence of described peptide is shown in the SEQ ID NO.2.
3. the nucleotide sequence of coding claim 1 or 2 described peptides.
4. an expression vector is characterized in that, contains the nucleotide sequence as claimed in claim 3 of at least one copy.
5. the host cell that contains the described expression vector of claim 4.
6. claim 1 or 2 described peptides are by chemical bond and HIV
48-57Peptide, the outer quilt of FHV-
35-49Peptide, HTLV-II Rex
4-16Peptide or BMV gag
7-25Peptide is puted together resulting product mutually.
7. the treatment or the medicinal compositions of preventing cancer is characterized in that, go up the claim 1 of significant quantity or 2 described peptides and acceptable accessories or carrier by treatment or prevention and are formed.
8. claim 1 or the 2 described peptides purposes in the medicine of preparation treatment or preventing cancer.
9. the purposes of the described product of claim 6 in the medicine of preparation treatment or preventing cancer.
10. purposes as claimed in claim 8 or 9 is characterized in that described cancer is selected from lung cancer, liver cancer, cancer of the stomach, colorectal carcinoma, the rectum cancer, the esophageal carcinoma, mammary cancer, leukemia, bladder cancer, cervical cancer or nasopharyngeal carcinoma.
11. claim 1 or 2 described peptides are used for the purposes that the enhancing gene toxin optionally kills and wounds the medicine of cancer cells in preparation.
12. purposes as claimed in claim 11, it is characterized in that described gene toxin is selected from Platinol, oxaliplatin, taxol, epirubicin, Dx, pirarubicin, daunorubicin, mitomycin, Dacarbazine, endoxan, gemcitabine or capecitabine.
13. purposes as claimed in claim 11 is characterized in that, described cancer cells is selected from the cancer cells of lung cancer, liver cancer, cancer of the stomach, colorectal carcinoma, the rectum cancer, the esophageal carcinoma, mammary cancer, leukemia, bladder cancer, cervical cancer or nasopharyngeal carcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101638521A CN101891802B (en) | 2009-08-11 | 2009-08-11 | Polypeptide or derivative product for treating or preventing cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101638521A CN101891802B (en) | 2009-08-11 | 2009-08-11 | Polypeptide or derivative product for treating or preventing cancer and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101891802A CN101891802A (en) | 2010-11-24 |
| CN101891802B true CN101891802B (en) | 2011-11-16 |
Family
ID=43101174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101638521A Active CN101891802B (en) | 2009-08-11 | 2009-08-11 | Polypeptide or derivative product for treating or preventing cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101891802B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317244B (en) * | 2019-06-18 | 2021-04-20 | 清华大学深圳研究生院 | RAGE (receptor for activating receptor) antagonistic polypeptide and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1292029A (en) * | 1998-01-28 | 2001-04-18 | 科里克萨有限公司 | Compounds for therapy and diagnosis for lung cancer and method for their use |
| CN1816564B (en) * | 2003-06-30 | 2010-11-24 | 洛桑大学 | Rasgap derived peptide for selectively killing cancer cells |
-
2009
- 2009-08-11 CN CN2009101638521A patent/CN101891802B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1292029A (en) * | 1998-01-28 | 2001-04-18 | 科里克萨有限公司 | Compounds for therapy and diagnosis for lung cancer and method for their use |
| CN1816564B (en) * | 2003-06-30 | 2010-11-24 | 洛桑大学 | Rasgap derived peptide for selectively killing cancer cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101891802A (en) | 2010-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108358973B (en) | Naphthalimide tetravalent platinum compound, preparation method and application thereof in preparation of antitumor drugs | |
| Şahin-Bölükbaşı et al. | Novel Silver-NHC complexes: Synthesis and anticancer properties | |
| Liu et al. | Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1 | |
| EP1855662A2 (en) | Methods and compositions for treating cancer | |
| CN101624443A (en) | Preparation method for amycin pro drug and application thereof | |
| KR102228272B1 (en) | Cancer-specific drug nanocomplex for synergistic anticancer effect | |
| Hao et al. | Nanoreactor of “butterfly effect” inciting a triple interlocked combination of starvation/chemo/metal ion therapy by remodeling tumor microenvironment | |
| CN101921313B (en) | Polypeptide for curing or preventing cancer or derivative product and application thereof | |
| Cao et al. | Novel indazole skeleton derivatives containing 1, 2, 3-triazole as potential anti-prostate cancer drugs | |
| CN101891802B (en) | Polypeptide or derivative product for treating or preventing cancer and application thereof | |
| CN107573384B (en) | A kind of iridium bipyridyl complex and synthetic method and the application in DNA nano medicament carrying system | |
| CN106466484B (en) | Multi-target ligand-drug conjugate with function of cell endocytosis mediation | |
| CN104804047B (en) | The preparation method and its usage of the ferrocene derivatives of novel nitrogen-containing oxygen radical | |
| CN104523674B (en) | A kind of composition for injection using oxaliplatin as main ingredient composition | |
| Xu et al. | Reduction-responsive dehydroepiandrosterone prodrug nanoparticles loaded with camptothecin for cancer therapy by enhancing oxidation therapy and cell replication inhibition | |
| CN109700761A (en) | A kind of cancer target is from carrier systems and preparation method thereof, application | |
| CN102030800A (en) | Abies holophylla triterpenoid compound, extraction separation thereof and application thereof | |
| KR101560339B1 (en) | Pharmaceutical composition and combined agent | |
| CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
| CN101317835B (en) | Application of cantharidin and its derivant in preparing sensitization medicament for tumour chemotherapy | |
| US9346849B2 (en) | Amino sugar-bound anti-cancerous noble metal complex | |
| CN110051858A (en) | The preparation of a kind of polysaccharide medicine composite nanoparticle and its antitumor activity | |
| CN106588996B (en) | Phthalocyanine aryl ruthenium complex and its preparation method and application | |
| CN102260319A (en) | Novel platinum coordination complex, and preparation method and application thereof | |
| CN114605517B (en) | Polypeptide LXP-7 with broad-spectrum anticancer effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190222 Address after: 519040 No. 6 Jinhai East Road, Sanzao, Jinwan District, Zhuhai City, Guangdong Province Patentee after: ZHUHAI TONGYUAN PHARMACEUTICAL CO.,LTD. Address before: Room 1602, 16th floor, Wujiawan Information Technology Building, Hongshan District, Wuhan City, Hubei Province Patentee before: Wuhan KatyGen Pharmaceuticals, Inc. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Peptides or derived products for the treatment or prevention of cancer and their applications Granted publication date: 20111116 Pledgee: Zhuhai Branch of China Construction Bank Co.,Ltd. Pledgor: ZHUHAI TONGYUAN PHARMACEUTICAL CO.,LTD. Registration number: Y2024980016363 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |